International Petroleum Corporation to release Q1 2025 Financial and Operational Results on May 6, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) — International Petroleum Corporation (IPC) (TSX, Nasdaq Stockholm: IPCO) will publish its financial and operating results and related management's discussion and analysis for the three months ending 31 March 2025, on Tuesday, May 6, 2025 at 07:30 CET, followed by an audiocast at 09:00 CET.
Follow the 2025 first quarter financial and operating results presentation starting at 09:00 CET live on
www.international-petroleum.com
or using the link or dial in details below:
Presentation Link:
https://ipc.videosync.fi/2025-05-06-q1
International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC's shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm under the symbol 'IPCO'.
For further information, please contact:
Forward-Looking Statements
This press release contains statements and information which constitute 'forward-looking statements' or 'forward-looking information' (within the meaning of applicable securities legislation). Such statements and information (together, 'forward-looking statements') relate to future events, including the Corporation's future performance, business prospects or opportunities. Actual results may differ materially from those expressed or implied by forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Forward-looking statements speak only as of the date of this press release, unless otherwise indicated. IPC does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by applicable laws.
All statements other than statements of historical fact may be forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, forecasts, guidance, budgets, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as 'seek', 'anticipate', 'plan', 'continue', 'estimate', 'expect', 'may', 'will', 'project', 'forecast', 'predict', 'potential', 'targeting', 'intend', 'could', 'might', 'should', 'believe', 'budget' and similar expressions) are not statements of historical fact and may be 'forward-looking statements'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025
Data from the ongoing Phase 2a study shows a 100% disease control rate with 45% of patients with advanced cutaneous T-cell lymphoma achieving an objective response: One complete response, three partial responses, and five stable diseases in nine evaluable patients so far Robust immune activation supporting clinical activity observed Study continues to enroll patients; dose optimization phase to follow. LUND, SE / / June 12, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated positive data from the ongoing Phase 2a dose expansion study of BI-1808 monotherapy in cutaneous T-cell lymphoma (CTCL). The data will be presented in a poster at the European Hematology Association (EHA) 2025 congress, June 12-15 in Milan, Italy. As of the cut-off date May 15, 2025, data showed a 100% disease control rate in nine evaluable patients with CTCL. Forty-five percent of these patients achieved an objective response, with one patient achieving a complete response (CR), three achieving a partial response (PR), and five exhibiting stable disease (SD). Additionally, two patients with peripheral T-cell lymphoma (PTCL) were evaluable, of which one showed a PR, while the other showed SD. Overall, BI-1808 monotherapy demonstrates promising clinical activity and robust immune BI-1808 was well tolerated, with all treatment-related adverse events reported as mild or moderate (Grade 1-2). Notably, no Grade 3 or higher adverse events were observed. Transient disease flares, including skin peeling, erythema, and pruritus during the first weeks of treatment, were observed and shown to be associated with the BI-1808 immunologic mechanism. These flares coincide with regulatory T cell depletion and influx of CD8+ T cells into the skin, indicating on-target immune activation. Immunofluorescence multiplexing, starting at week 5, further confirmed increased CD8+ T cell infiltration and elevated granzyme B, supporting the drug candidate's mechanism of action. "These results reinforce the potential of BI-1808 as a novel immune-modulating therapy for CTCL," said Martin Welschof, Chief Executive Officer of BioInvent. "The early and sustained immune activation observed, combined with a favorable safety profile and 100% disease control rate, support the value of our anti-Tumor Necrosis Factor Receptor 2 (TNFR2) approach. We believe that these early Phase 2a data represent a meaningful milestone in our mission to deliver transformative therapies for difficult-to-treat patients, and we look forward to advancing BI-1808 into later-stage studies." Details of the poster:Title: Robust Single Agent Activity of BI-1808, a Tumor Necrosis Factor Receptor 2 (TNFR2) Blocker/Depleter, in Cutaneous T Cell Lymphoma (CTCL) PatientsSession Date and Time: June 13, 2025, 6:30-7:30 pm CESTSession Title: Poster Session 1Lead Author: Stefan K. Barta, University of Pennsylvania Hospital, Philadelphia, PA, USAAbstract Number: PF961 The poster will be posted to the Scientific Publications section of the company website ( ). The safety and preliminary efficacy of BI-1808 monotherapy are currently being evaluated in a sub-cohort (Part A) of the ongoing Phase 2a ( NCT04752826 ) study in patients with T-cell lymphomas, including CTCL. The study is expected to enroll 20 patients at a signal-seeking dose, after which a dose optimization phase is planned to be initiated. In April 2025, BioInvent received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for BI-1808 for the treatment of CTCL and in March 2025, Orphan Drug Designation was received from the same agency for BI-1808 in T-cell lymphoma (TCL). About BI-1808The anti-TNFR2 antibody BI-1808 is part of BioInvent's tumor-associated regulatory T cells (Treg)-targeting program. TNFR2 is particularly upregulated on Tregs of the tumor microenvironment and has been shown to be important for tumor expansion and survival, representing a new and promising target for cancer immunotherapy. BI-1808 is a first-in-class drug candidate in clinical development for the treatment of solid tumors and blood cancer. BI-1808 has shown single agent activity and excellent tolerability in an ongoing Phase 2a study and signs of efficacy and favorable safety profile in combination with pembrolizumab in the ongoing Phase 1/2a study. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at . For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-12 09:00 CEST. Attachments BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025 SOURCE: BioInvent International View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Lundin Mining Announces 2025 Capital Markets Day
VANCOUVER, BC, June 11, 2025 /CNW/ - (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation ("Lundin Mining" or the "Company") is pleased to announce the executive management team will be presenting an outlook for the Company on Wednesday, June 18, 2025, from 8:00 am to 12:00 pm ET at Lundin Mining's Capital Markets Day. Webcast / Conference Call Details:Date: Wednesday, June 18, 2025Time: 8:00 AM ET | 1:00 PM BSTWebcast: WEBCAST LINK or An archive of the webcast will be available at after the event. About Lundin Mining Lundin Mining is a diversified base metals mining company with operations or projects in Argentina, Brazil, Chile, and the United States of America, primarily producing copper, gold and nickel. SOURCE Lundin Mining Corporation View original content to download multimedia:
Yahoo
7 hours ago
- Yahoo
How I'd Allocate $10,000 Across These 3 Brilliant TSX Stocks for Growth and Income
Written by Puja Tayal at The Motley Fool Canada Investing in the stock market is not just about buying the dip and selling the rally. Knowing what you want from your money is crucial in determining which dips to buy. If you want to put $10,000 to work and help you get growth and income for the long term, you might have to choose two different stocks. However, there are a few stocks that can give you both. A good strategy could be to invest in three stocks – one for income, one for growth, and one for both. Starting with the stock that gives you income and even grows your money in the long term. The non-prime lender goeasy (TYSX:GSY) is a stock that has given regular quarterly dividends and even grown them by strong double digits in 10 out of the last 11 years. goeasy is in the business of giving unsecured and secured loans through easyfinancial and easyhome brands. Over the years, it expanded its business horizontally by Offering new loan products — point-of-sale financing and automotive loans — and ancillary services like creditor insurance and warranty coverage; Expanding its distribution channel; Expanding its Canadian presence; and Strengthening its underwriting model to give loans to more customers while controlling credit risk. All these efforts have helped the lender increase its loan portfolio over the years and grow its share price by 800% in the last 10 years, which is 10 times the 79% rally of the TSX Composite Index. goeasy stock also offers a 3.8% dividend yield from the interest earned on the loan portfolio. The yield might look small, but if you had held the stock for 10 years, the $0.5 dividend per share would have grown to $5.84. A $3,000 investment in goeasy in June 2015 would have bought you 154 shares, which are now worth $23,639, and have increased your annual dividend from $77 to $899. Now is a good time to buy and hold the stock, as high credit risk has pulled down the share price. It is trading at a forward price-to-earnings ratio of 8.71, below its five-year average of 10.76. Business jet maker Bombardier (TSX:BBD.B) is a growth-oriented stock that can give you double-digit capital appreciation. Although the management is considering paying dividends in the next two to three years as its free cash flow (FCF) stabilizes, meaningful returns will come from capital appreciation. Here's why. Bombardier's main business is selling business jets. The order book for business jets can fluctuate, which would be reflected in its share price. For instance, the company completed the flight test of its next-generation Global 8000 in May, hinting at a better product mix in the future. Moreover, the defence and pre-owned business jet verticals present opportunities to boost orders and grow the share price. As for dividends, the business jet maker could use its recurring revenue from after-market services. A $3,000 investment in Bombardier stock in June 2020 is now $23,000. This stock tends to rally in the second half as aircraft delivery volumes surge and free cash flow comes in. Although the stock has already jumped 32% from its April dip, there is more upside as the company secures orders for Global 8000. You have the growth, now comes the dividend. Many dividend stocks intend to help you generate passive income for your retirement. They offer dividend-reinvestment plans (DRIP) and even grow them annually to adjust for inflation. You can bank on them to pay dividends in every market condition, thereby complementing your pension. Telus (TSX:T) has a 21-year history of growing dividends. It offers DRIP to automate your retirement planning by accumulating dividend-paying shares. You can be assured about the dividends as Telus pays them using subscription money. The dividend-growth rate has slowed from 7-10% to 3-8% as competitive pricing and network sharing reduce its margins. However, it is working on monetizing its 5G network, which will help strengthen its balance sheet and FCF. This could help it grow dividends for years to come. You could consider investing $4,000 now while the stock trades closer to its 10-year low and lock in a 7.4% dividend yield. The post How I'd Allocate $10,000 Across These 3 Brilliant TSX Stocks for Growth and Income appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Puja Tayal has no position in any of the stocks mentioned. The Motley Fool recommends TELUS. The Motley Fool has a disclosure policy. 2025 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
